How Genetic Variants Shape Immune-Cell Gene Expression

Introduction

People carry millions of genetic differences, most of which have little measurable effect. Some, however, influence protein production, cellular signaling, inflammation, and disease susceptibility. These effects can vary substantially between immune-cell types.

Recent research shows that both rare and common genetic variants can regulate gene expression in individual immune cells. Single-cell analysis allows researchers to study how variants affect T cells, B cells, monocytes, natural killer cells, dendritic cells, and other populations rather than treating the immune system as a uniform tissue Source 1.

This perspective helps explain how inherited variation contributes to immune-cell function, inflammation, disease risk, and treatment response. Researchers increasingly combine genotype data with single-cell gene-expression and chromatin-accessibility maps to connect a DNA variant with a regulatory element, target gene, cell state, and disease mechanism.

Common and Rare Genetic Variants

Common Variants

Common genetic variants occur relatively frequently in a population. Many are single-nucleotide variants, although larger changes can also be common. Individual variants usually have modest effects, such as slightly increasing or reducing gene activity or altering the response to an inflammatory signal.

Genome-wide association studies identify relationships between common variants and traits such as autoimmune disease, infection outcomes, and inflammatory markers. Many disease-associated variants occur outside protein-coding regions, in regulatory DNA that controls when, where, and how strongly genes are expressed.

A variant may have little effect in a resting cell but become important after activation. It may also regulate a gene in monocytes while having no measurable effect in T cells. Single-cell analysis helps identify these contexts.

Rare Variants

Rare variants occur in a small proportion of individuals. Some alter protein-coding sequences and substantially affect protein function. Others occur in promoters, enhancers, transcription-factor binding sites, or other regulatory regions.

A rare variant can have a stronger effect than an individual common variant, but its impact may be limited to carriers. Large cohorts, accurate sequencing, and functional experiments are therefore needed to distinguish genuine effects from chance observations.

Rare does not automatically mean damaging. Researchers assess a variant’s location, predicted effect, inheritance pattern, cellular activity, and relationship to relevant traits. A medRxiv preprint has examined how rare and common variants influence cell-type-specific gene expression in human blood. Because it is a preprint, its findings require independent evaluation and should not be considered established clinical evidence Source 9.

Why Both Classes Matter

Common variants reveal broad population-level patterns, whereas rare variants can expose stronger or more specific effects. The influence of either class may depend on:

• Immune-cell type.
• Activation state.
• Regulated gene or pathway.
• Chromatin landscape.
• Environmental signals.
• Medication, age, infection, or disease activity.

Genetic risk operates within a biological context rather than through DNA sequence alone.

Why Single-Cell Analysis Matters

Limits of Bulk Gene Expression

Bulk RNA sequencing measures gene activity across many cells and produces an average signal. It can conceal effects limited to a small or specialized population. A variant may strongly increase expression in a subset of monocytes while having no effect in lymphocytes. If monocytes make up only a fraction of a sample, the overall change may appear weak.

Bulk analysis can also confuse gene-expression changes with changes in cell composition. A sample may contain more inflammatory genes because individual cells are more active, because it contains more inflammatory cells, or because both processes occurred.

What Single-Cell Methods Reveal

Single-cell RNA sequencing measures gene expression in individual cells. Researchers can identify each cell’s type and state, then test whether a variant is associated with expression differences within that population.

This approach can show:

• Which immune cells respond to a variant.
• Whether the effect occurs in resting or activated cells.
• Which genes and pathways are affected.
• Whether the effect differs between individuals.
• Whether a disease signal reflects cellular regulation or composition changes.

Researchers can identify cell-specific expression quantitative trait loci, or eQTLs. A single-cell eQTL connects a genetic variant with gene-expression variation in a particular cell type or state.

Linking Genotype to Function

A typical analysis involves five steps:

1. Genotype or sequence participants’ DNA.
2. Profile gene expression in individual immune cells.
3. Classify cells by type and activation state.
4. Test whether variants correlate with expression changes.
5. Map affected genes to pathways and disease traits.

These associations do not prove causation. A variant may be linked to a functional change because it is near the true causal variant, because both are inherited together, or because another factor influences both genotype and expression. Functional experiments are required to validate the mechanism.

How Variants Influence Immune-Cell Gene Expression

Regulatory Effects

Many disease-associated variants occur outside protein-coding regions. They can influence promoters, enhancers, insulators, and transcription-factor binding sites by:

• Increasing or reducing transcription-factor binding.
• Changing enhancer activity.
• Altering communication between enhancers and promoters.
• Modifying the timing or level of gene expression.

The result may be more or less messenger RNA from a target gene. In immune cells, even modest changes can affect cytokine production, antigen presentation, migration, and responses to microbial signals.

Cell-Specific Effects

The same variant can have different effects in different immune-cell types because regulatory DNA is active only when the necessary transcription factors and chromatin environment are present.

For example, an enhancer may be open and functional in an activated monocyte but closed in a resting T cell. A variant within that enhancer will therefore have a cell-specific effect. The same sequence may also respond differently to interferons, bacterial products, steroid hormones, or other signals.

Rare Variants and Strong Local Effects

Rare variants can disrupt regulatory sequences or protein function more substantially. Their effects may appear only in carriers or in a small immune-cell population. Single-cell profiling can show whether a variant affects a specific cell type or state.

Rare-variant findings require replication. Researchers must consider sequencing quality, ancestry, relatedness, disease status, sample size, and multiple statistical tests.

Common Variants and Distributed Effects

Common variants often produce smaller changes, but many can combine to influence immune responses. A variant may slightly increase inflammatory-gene expression in activated monocytes, while others alter T-cell signaling or epithelial–immune communication. Their combined effects can contribute to polygenic disease risk.

Single-cell data identify the cellular context in which each effect operates, improving interpretation of polygenic risk and helping distinguish functional variants from nearby correlated signals.

Genetic Variation and Chromatin Accessibility

Chromatin accessibility describes how available a DNA region is to transcription factors and other regulatory proteins. Open chromatin allows regulatory proteins to bind, while closed chromatin restricts access. Accessible regions often contain active promoters or enhancers and can change when cells differentiate, become activated, encounter infection, or enter an inflammatory state.

Single-cell ATAC sequencing and related methods measure accessible chromatin in individual cells. A variant can change the DNA sequence recognized by a transcription factor, strengthening or weakening binding. This may alter chromatin accessibility, enhancer activity, and expression of a nearby or connected gene.

Nature-reported findings indicate that genetic variants can influence chromatin accessibility at the single-cell level, connecting individual genetic differences with cell-specific regulatory changes and disease risk Source 5.

Combining RNA and chromatin data can connect:

1. A genetic variant.
2. An accessible regulatory element.
3. A target gene.
4. A specific immune-cell type.
5. A biological pathway.

This model is stronger than either dataset alone, but it does not establish direct causality. CRISPR perturbation, reporter assays, and other experiments are needed for confirmation.

Cell Type and Disease Risk

A disease-associated variant may intensify inflammatory signaling in monocytes but have little effect in T cells. Another may affect T-cell differentiation while remaining inactive in innate immune cells. A variant can also change how one cell responds to a signal produced by another.

Inflammatory Bowel Disease

Inflammatory bowel disease involves persistent or recurring gastrointestinal inflammation. Genetic susceptibility is one factor alongside the microbiome, intestinal-barrier function, diet, medication, and other environmental influences.

Nature-related findings indicate that inflammatory bowel disease-associated variation differs across cell types, supporting a model in which cellular context shapes intestinal inflammation Source 7.

Some variants may influence innate immune cells, including monocytes and dendritic cells. Others may act in adaptive immune cells, such as T or B cells. These findings do not show that one cell type causes all disease activity; they show that inherited risk can enter different biological pathways depending on the cell involved.

From Association to Mechanism

Identifying a disease-associated variant is only the first step. Researchers must determine which cell type is affected, which gene is regulated, whether expression increases or decreases, which pathway changes, and how the effect alters cell behavior.

A complete regulatory model may integrate:

• Genotype data.
• Single-cell RNA sequencing.
• Chromatin-accessibility profiles.
• Epigenetic maps.
• Protein measurements.
• Clinical disease data.
• Tissue-specific information.

Candidate mechanisms can be tested with CRISPR-based perturbation, reporter assays, cell-culture experiments, Perturb-seq, and patient-derived cellular models. These methods help establish whether changing a variant or regulatory element changes gene expression and immune-cell behavior.

Potential Impact on Diagnosis and Treatment

Cell-specific effects may improve the biological interpretation of genetic risk scores. Researchers can prioritize genes and pathways that are influenced by disease-associated variants, active in relevant immune cells, connected to inflammation, and accessible to pharmacological intervention.

This could support treatments aimed at disease-driving cell states rather than broad immune suppression. Future precision-medicine approaches may combine a patient’s genetic profile with the affected immune-cell pathway and molecular disease subtype.

Clinical implementation requires prospective trials. A molecular difference must reliably predict treatment response, safety, or disease progression before it can guide routine care. These findings provide a foundation, not an immediately available diagnostic test.

Limitations and Open Questions

Single-cell datasets face technical and statistical challenges. Sparse expression measurements, dropout events, batch effects, unequal cell counts, sample handling, and sequencing depth can distort comparisons.

Rare-variant analysis requires large, well-characterized cohorts. Apparent cell-specific effects may also reflect age, medication, infection, disease activity, or immune-cell activation. Blood is accessible but may not represent immune cells in affected tissues such as the intestine, lung, skin, or joints.

Important questions include:

• Which rare variants have the strongest effects in specific immune-cell states?
• How do environmental exposures modify variant-dependent expression?
• Do genetic effects change during infection or disease flares?
• Which variant–gene links are shared across diseases?
• Can cell-specific regulatory maps predict treatment response?

Conclusion

Rare and common genetic variants both shape gene expression in individual immune cells. Common variants often produce subtle, distributed effects, while rare variants may cause stronger or more localized changes. Neither class operates independently of cellular context.

Single-cell analysis reveals effects hidden by bulk measurements and shows whether a variant acts in a monocyte, T cell, B cell, natural killer cell, dendritic cell, or another population. Chromatin-accessibility data add another layer by showing how variants may alter regulatory DNA before gene-expression changes appear.

For inflammatory bowel disease and other immune-mediated conditions, these maps can clarify disease mechanisms, prioritize therapeutic targets, and support more precise risk models. Linking genetic variation to specific cells and regulatory programs may improve diagnosis and treatment, but clinical use requires functional validation and prospective evidence.

FAQ

How do rare and common genetic variants differ?

Common variants occur frequently and often have small individual effects. Rare variants occur less frequently and may have stronger effects in carriers. Both can influence immune-cell gene regulation and disease susceptibility.

Why is single-cell gene-expression analysis important?

It shows how variants affect specific cell types instead of producing an average across a mixed sample. This helps identify the immune cells and pathways that contribute to disease risk.

How can genetic variants affect chromatin accessibility?

A variant can alter a transcription-factor binding site or another regulatory sequence. This may change whether DNA is open, modify enhancer activity, and affect gene transcription.

What does this research suggest about inflammatory bowel disease?

It suggests that inflammatory bowel disease-associated variants can act differently across immune-cell types. This information may clarify disease mechanisms and support targeted treatment research.

Can these findings predict disease risk or treatment response?

Not by themselves. They may improve future risk models and precision-medicine strategies, but clinical use requires large, diverse cohorts, clinical validation, and prospective studies.

Are genetic variants the only factors determining immune-cell behavior?

No. Immune-cell function also depends on infection, environment, age, medication, epigenetic state, tissue location, and disease activity. Genetic variation is one part of a broader biological system.